The patient depicted had kidney SOT
#PTLD #DLBCL (and molecular double hit to boot) so likely w/ prominent T-cell suppression/exhaustion.
👀 Still fascinating nonetheless to have good CR to 20/3 Bispecific after blowing through 5 previous consecutive therapies (no response x 5).
The population-pharmacokinetic models of CART suggest that some failures could be inadequate CART expansion. So it's plausible that CD20 could remain a viable target for another approach like 20/3 bispecific t-cell engager.